Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3TR-PARTNER-RA
2024-511470-79-00Phase 4Authorised
- Sponsor
- Queen Mary University of London
- Start
- Feb 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 4, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Abatacept with Placebo comparator (2 arms). Primary endpoint: Change in Clinical Disease Activity Index. Planned start Feb 2025; status: authorised.
02
Drugs
abatacept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2024-511470-79-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511470-79-00.